0001193125-20-266442.txt : 20201211 0001193125-20-266442.hdr.sgml : 20201211 20201008173028 ACCESSION NUMBER: 0001193125-20-266442 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 5 FILED AS OF DATE: 20201008 FILER: COMPANY DATA: COMPANY CONFORMED NAME: InMed Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001728328 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: SUITE 310, 815 W. HASTINGS STREET CITY: VANCOUVER STATE: A1 ZIP: V6C 1B4 BUSINESS PHONE: (604) 669-7207 MAIL ADDRESS: STREET 1: SUITE 310, 815 W. HASTINGS STREET CITY: VANCOUVER STATE: A1 ZIP: V6C 1B4 CORRESP 1 filename1.htm CORRESP

LOGO

 

  DANIEL M. MILLER
  Partner
  (604) 630-5199
  FAX (604) 687-8504
  miller.dan@dorsey.com

October 8, 2020

Division of Corporation Finance

U.S. Securities and Exchange Commission

100 F Street N.E.

Washington, D.C. 20549

USA

Attention: Division of Corporation Finance, Office of Life Sciences

 

Re:

InMed Pharmaceuticals Inc.

Amendment No. 3 to Registration Statement on Form S-1

Filed September 15, 2020

CIK No. 0001728328

Dear Sirs and Mesdames:

On behalf of our client, InMed Pharmaceuticals Inc. (the “Company”), and pursuant to the Securities Act of 1933, as amended (the “Act”), and the rules and regulations thereunder, we transmit for your review the Company’s responses, as we have been informed by the Company, to the comment included in the Staff’s letter of comments, dated September 22, 2020 (the “Comment”), in respect of the above noted registration statement submission. The Company’s response below is keyed to the Comment.

Amendment No. 3 to the Registration Statement on Form S-1 filed September 15, 2020

Prospectus Summary

Overview, page 2

 

1.

We note your disclosure on page 4 that to date you have safety data with INM-755 in 22 healthy adult volunteers and that a regulatory application was approved on April 17, 2020 for a second Phase 1 clinical trial in healthy volunteers. Please revise your pipeline table and your Risk Factor on page 29 to make it clear that your clinical development to date has been conducted outside the U.S.

The requested revisions have been made on page 29 of the Registration Statement under the heading “Risk Factors”, and in the tables on page 3 and page 67 of the Registration Statement.

 

LOGO

   LOGO
U.S. Securities and Exchange Commission   
October 8, 2020   
Page 2   

Should you have further comments or require further information, or if any questions should arise in connection with this submission, please call the undersigned at (604) 630-5199. You also may email me at miller.dan@dorsey.com or fax me at (604) 687-8504.

 

Yours truly,
/s/ Daniel M. Miller
Daniel M. Miller

 

cc:

Eric A. Adams

Bruce S. Colwill

        InMed Pharmaceuticals Inc.

 

LOGO

GRAPHIC 2 g37315g1007143256630.jpg GRAPHIC begin 644 g37315g1007143256630.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^J]S?6UG MM$\RHS?=7JS?0=365XOUU_#WA^6\A4-.S"*+/0,>Y^F":3PSI/V:QCOKMS<: MC@H U8[B67!2V=5/>4[?TY-6:** (I6=!E>1Z!SS;%]0^)4>I:YK?BK6H6%TT4<-G<>6J@'\1^0H ]\HKS#_A2M ME_T-WBG_ ,#A_P#$UF?#"[U?1_B%X@\'W>K7&I6-FN^%[EBSJ<^I_E0![%17 MAOQ=OIV^(WA_2YO$5WHVF3QGSIH9S&%YZG!Q^)J3_A%/!_\ T5[5/_!W'0![ M=17A'A/5+C1/BS;:!H?BJZ\1Z1:':W&K?%/Q#:W[IF:!9I0$;T'RG^= ' MTU17A.C^&[K4IEU#X>?$J^U&XM)4%S#J,KE-I]01ST/&/Q%>O>)='NM>\-7> MF6VI3:=>AH V**\1T[XC^(OAO=#0_B%9SW5LH(M=4MQ MO,H'0$G&[]&'?/6BQO/'/Q:U:"]M9KCPWX6@E#QNC$2W&#ZC[W_H(]S0![:: M*** ,GQ+H/[/>0J$5V^Y, M!P"IZ9KHJ9+#'.A26-74]F&10 ^BJZ6:0X$+R1J/X0V1^1JQ0 A. 3SQZ"N7 MUB*.]U.TN=1;R[6S?S(;91NEF?L2HZ#VKI)8FE&,KM]"#_C4(L0,XD,>>OE* M%S^/6@#C98F;Q /$FNK]G6%=EC8#YI6]R!W]O>K?A_0[Z\\13^)=7C\F60;; M:W/6-?4^^*ZF#3[2WD,L<"^:>LC?,Q_$\U9H *\V^,WAW6/$7ANQ31K)KR>W MNUE:)7"DC\:])JM>7B642NZ2.7<(JQKDDF@#SR'QMX[AMXXO^%9W1V(%S_:, M?.!]*Q=B,X,^^<2RR =N.OTP!7K(U6V-I)<$NHC;:R M,A#AO3'K34U:!H9W>.:)H!N>*1,,!V..] $&D^'[31?#4.AV>5MXH#"K'J>, M9/O7DGA>#XA_#AM0TJV\(IK-E)<--%/%=*G7_/<"O8X=5@E$F])H2B>85E3! M*^HHBU2*2&25H+B)47?^\CQN7U'K0!Y[_P )U\1O^B9R?^#!?\*B^&WACQ*/ M&&M>+O$EG'I\U^-D=HKAB!GJ<$\5Z,FJ(UL]P]MG/K0!YEXZ\!7?BGXG>'[R?3EN]%BC*W9:0 #G.",Y_*NCD^% M'@62)D/ANS7<,94$$?0YKIKO4H+.X@AEW[YCA=JY ^M6+B=+:!YI,[$&3@9- M 'D7@OP'K_P]^($L&FVT-[XZ8J4ZA L5Q*2VVW;;)\O? /' MKUH \BBU3Q:L2K-\&M.>0##,DD*@GV&TX_.LO4/#/BKQMK^CAO MEX9ALYQ+ M+>1R)N*CM\N"?ICKZ5[D][&DDD:I(\B()"J+DD'TJL-;MA8/>RQSQ0*P4M)' MUYQT'O0!C?$G2+[7? &JZ=IL!GNY8OW<88 L00<<\5Y;H-KXCT?0[73Y_@Y8 M7DL";6N)'BW2'U.03G\:]S?4+>,3$L2(8Q*Q49^4YQCUZ5$FJ(;62X>VNHHX MP&/F1X)'J!F@#R>&?XCWYN@8F!4>H '\B?I7LRY"@, M'=3\3>!&L=)M/M5VMS'(L890< X)&2!WKM-*MWM-'L;:10KPV\<;*O0$* M<5-%<1S2S1H3NA8*^1W(!_D155=7A,XC,-PJF4PB4Q_(6SC&?J,4 7C10:* M%HHHH **** "BBB@ HHHH *IZC;SW"0FW\O?%*),2$@' /< ^M%% %5M,N); M>9I)8Q=22K*-H.Q2O0>IX[TC:;=72WDERT*33QB)5C8E5 ]\ T44 %IH[6+7 M'D.A$L8"M+ERIQTY/*^U1P:3<+#=(5@@66/8(HG8H6_O8(&WZ"BB@"QI5A)9 M0M%)! BD 'RY6?=]=PJ?3;%=/M/(4*/F+';[FBB@#/U72+N\OEN;>6)70#RG M#[9/%3:582643Q/!!&I '[N5WR M??<.*** )],L4TZR%NBJ/G9CM]R2/TP/PJ*6WO8]4DNK86[I)$B$2.RD8+'L M#ZT44 $5O>P:C2,/-YSRJQ8D#)) /'!.,X-%% &B:*** /__9 end GRAPHIC 3 g37315g1007144516198.jpg GRAPHIC begin 644 g37315g1007144516198.jpg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end GRAPHIC 4 g37315g1007145335208.jpg GRAPHIC begin 644 g37315g1007145335208.jpg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end GRAPHIC 5 g37315g1007145359809.jpg GRAPHIC begin 644 g37315g1007145359809.jpg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end